- Trial phase
- Preclinical
- Time to market
- BMN 430 is at the preclinical stage, still working to identify a lead candidate. Assuming successful preclinical development, IND-enabling studies, and regulatory clearance, clinical trials would likely not begin before 2028 at the earliest. Commercialization, if successful, is many years away (likely 2030s).
- Why 2/10
- BMN 430 is a preclinical-stage program with no scheduled hard catalyst (no PDUFA, no pivotal readout, no AdComm) in the next ~12 months. It is one of several early pipeline additions at a company with nine commercial products and a broad clinical pipeline, making it a very small portion of BioMarin's overall value. Per the impact score rubric, a preclinical program with no dated binary catalyst cannot exceed 5, and as a minor program in a large pipeline, it scores 2.
BMN 430 has no hard dated catalyst in the next 12 months. The next milestone to watch is selection of a lead ASO candidate from preclinical studies, which could be announced in 2027. For BioMarin investors, the far more material near-term catalysts are the VOXZOGO hypochondroplasia PDUFA (target action date May 30, 2027) and commercial execution of the recently acquired Amicus portfolio (GALAFOLD, POMBILITI+OPFOLDA).
Price Chart
Executive Summary
BMN 430 is a preclinical antisense oligonucleotide (ASO) therapy for ReNU syndrome, a rare neurodevelopmental disorder discovered in 2024 and caused by variants in the RNU4-2 gene. BioMarin (BMRN) entered a global exclusive license and collaboration with the n-Lorem Foundation in July 2026 to develop this first-in-disease candidate. The ASO targets the RNU4-2 (n.64_65insT) variant, which accounts for roughly 75% of ReNU syndrome cases. As of the Q3 2026 earnings report (November 2, 2026), preclinical studies are underway to identify a lead ASO candidate. No clinical trials have been initiated, no FDA catalysts are scheduled, and no generic/INN name has been assigned. BMN 430 is one of several early-stage pipeline additions BioMarin made in 2026 and represents a very small portion of the company's overall value, which includes nine commercial therapies and a broad pipeline.
How It Works
BMN 430 is an antisense oligonucleotide (ASO), a type of precision genetic medicine made from short synthetic DNA-like molecules. It is designed to target and bind to a specific genetic mutation (the n.64_65insT variant in the RNU4-2 gene) that causes ReNU syndrome, a rare neurodevelopmental disorder. By binding to the faulty genetic instructions, the ASO aims to correct or compensate for the underlying genetic defect. This is similar in concept to other ASO drugs that have been approved for rare genetic conditions.
Trial Status
BMN 430 is in preclinical development. The collaboration between BioMarin and n-Lorem Foundation was announced in July 2026. As of BioMarin's Q3 2026 earnings report (November 2, 2026), preclinical studies are underway to identify a lead ASO candidate. No clinical trials have been initiated and no regulatory filings have been made.
The Two-Sided Case
Upcoming Catalysts
- Selection of a lead ASO candidate from ongoing preclinical studies (no date announced, potentially 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report